Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17)

Y J Choi 1,2, S H Lee 3, J-L Lee *,1,4, J-H Ahn 1,4, K-H Lee 4, D You 5, B Hong 5, J H Hong 5 and H Ahn 5

1 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; 2 Division of Hemato-oncology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea; 3 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; 4 Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea and 5 Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Background: Pemetrexed has shown a favourable response rate of about 30% with minimal toxicity when used as a single agent for treatment of advanced urothelial carcinoma. This phase II study evaluated the efficacy and safety of pemetrexed plus cisplatin in advanced urothelial carcinoma.

Methods: This multicentre, single-arm, open-label, phase II clinical trial enrolled patients who had advanced urothelial carcinoma, ECOG PS 0–2, and measurable disease. Pemetrexed 500 mg m⁻² with cisplatin 70 mg m⁻² on day 1 were administered every 3 weeks. The primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity.

Results: A total of 42 patients were enrolled (median age, 66 years; ECOG 0–1, 100%; visceral metastasis, 54.8%; recurrent disease, 57.1%). Twenty-seven partial responses for an ORR of 64.3% (95% CI, 49.2%–77.0%) were documented. Seven patients had stable disease. Median PFS and OS were 6.9 (95% CI, 6.2–7.6) and 14.4 (95% CI, 10.4–18.4) months, respectively. Grade 3 or 4 neutropenia was observed in 28.6% of patients. No patients experienced febrile neutropenia.

Conclusion: The combination of pemetrexed and cisplatin is active, and well tolerated in patients with advanced urothelial cancer as a first-line treatment.

Urothelial carcinoma is a common cancer that remains highly lethal if diagnosed at an advanced stage. Worldwide, it is estimated that there were 386,300 new cases of bladder cancer in 2008, resulting in 150,200 deaths (Jemal et al., 2011). The survival of patients with advanced urothelial carcinoma who receive best supportive care ranges from 4 to 6 months. The overall survival (OS) has doubled with combination chemotherapy, and systemic chemotherapy is the most useful option in these patients. Cisplatin is thought to be the most effective chemotherapeutic agent, with a response rate of about 30% (Rossof et al., 1979; Herr, 1980; De Lena et al., 1984). Cisplatin-based chemotherapy, such as methotrexate, vinblastine, Adriamycin, and cisplatin and gemcitabine/cisplatin,
continues to be the standard first-line treatment for advanced urothelial cancer, resulting in an objective response rate (ORR) of 45–60%, a median progression-free survival (PFS) of 7–8 months, and a median OS of 14–15 months (von der Maase et al, 2000; Sternberg et al, 2006). Nevertheless, long-term survival is rare and haematologic toxicity is frequent. Thus, a more effective and safer therapy is required.

Pemetrexed is a potent inhibitor of thymidylate synthase (TS) (Taylor et al, 1992; Schultz et al, 1999) and other folate-dependent enzymes, including dihydrololate reductase and glycaminide ribonucleotide formyltransferase (Shih et al, 1998). Pemetrexed has demonstrated a favourable response with minimal toxicity when used as a single agent in first-line and second-line treatment of advanced urothelial carcinoma. Response rates of 32% and 8–28% have been found for first-line and second-line settings, respectively (Paz-Ares et al, 2003a; Sweeney et al, 2006; Galsky et al, 2007). Excessive toxicity can largely be prevented by supplementation with low-dose folic acid and vitamin B12 (Sweeney et al, 2006). The combination of pemetrexed with cisplatin has already been attempted for various types of malignancies, demonstrating superior efficacy compared with gemcitabine plus cisplatin or cisplatin alone in patients with nonsquamous non-small-cell lung cancer (Scagliotti et al, 2008) and malignant pleural mesothelioma (Vogelzang et al, 2003). In addition, pemetrexed has an excellent safety profile and a convenient administration schedule. Therefore, this combination is now the standard regimen for first-line treatment of these malignancies.

This phase II trial was conducted to evaluate the efficacy and toxicity of the combination of pemetrexed with cisplatin in patients with advanced urothelial carcinoma.

**PATIENTS AND METHODS**

**Study design and patients.** This multicentre, single-arm, open-label, phase II clinical trial evaluated the combination of pemetrexed and cisplatin in advanced urothelial carcinoma. To be enrolled, patients had to have a histologically confirmed diagnosis of urothelial (transitional cell) carcinoma, recurrent disease that was not amenable to local therapy or newly diagnosed distant metastatic disease, and a measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 criteria. Patients had to be aged between 18 and 80 years, have an ECOG performance of 0–2. Patients were also required to have adequate bone marrow, renal, and hepatic function, which was indicated by neutrophils $> 3000 \text{ ul}^{-1}$, platelets $\geq 100000 \text{ ul}^{-1}$, and hemoglobin $> 9 \text{ g dl}^{-1}$, serum creatinine $< 1.5 \text{ mg dl}^{-1}$ (if values were borderline, the creatinine clearance had to be $\geq 60 \text{ ml min}^{-1}$ by Cockcroft and Gault formula), total bilirubin $\leq 1.5$ times the normal limit, and alanine aminotransferase and aspartate aminotransferase $\leq 3$ times the upper limit of normal. Exclusions were made for the micropapillary subtype of urothelial carcinoma, other tumour types such as adenocarcinoma or squamous cell carcinoma, the presence or history of CNS metastasis, prior palliative systemic chemotherapy or immunotherapy (but prior local intravesical chemotherapy or immunotherapy and adjuvant or neoadjuvant cisplatin-based chemotherapy 1 year or more before enrolment was allowed), the presence of second primary malignancy, a peripheral sensory neuropathy grade 2 or worse, and other serious illness or medical conditions. All patients were informed of the investigational nature of this study and gave written informed consent to participate. The protocol was approved by the institutional review boards of participating institutions and Korea Cancer Study Group (2008-0176/KCSG GU10-17) and registered at ClinicalTrials.gov (NCT01490437).

**RESULTS**

**Patient characteristics.** Between July 2009 and June 2013, a total of 44 patients with advanced urothelial carcinoma were recruited from two cancer centres in Korea. Two patients were ineligible because of a different histology and concomitant malignancy and excluded from the analyses. A total of 42 patients enrolled in this study were assessable for safety analysis. Of these 42 cases, 41 were assessable for efficacy analysis per protocol. One patient failed to undergo post-baseline tumour assessment because of clinical deterioration during cycle 1 with the response status unknown. This patient was counted as an early progressor and as such, all of the 42 treated patients are included in the intent-to-treat analysis. At the time of analysis, 57.1% of the patients (24 of 42) had died. Baseline characteristics are presented in Table 1. Of note, patients were predominantly male with a median age of 66 years (range, 42–78 years) and all patients had good ECOG PS (0–1). Moreover, more than half of patients had visceral metastatic disease; especially, liver and bone metastases were observed in

**Treatment.** Patients were treated with pemetrexed $500 \text{ mg m}^{-2}$ for over 10 min and cisplatin $70 \text{ mg m}^{-2}$ over 60 min intravenously on day 1. All doses were based on actual body weight. Chemotherapy was repeated every 3 weeks for a maximum of eight cycles (unless there was earlier evidence of disease progression or intolerance of the study treatment). Patients received dexamethasone prophylaxis of 4 mg orally twice per day on the day before, the day of, and the day after each day 1 treatment. All patients received oral folic acid (350–600 $\mu$g) daily and a vitamin B12 injection (1000 $\mu$g) every 9 weeks, beginning 1 week before the first dose and continuing until 3 weeks after the last dose of the study treatment.

Patients requiring a dose reduction of pemetrexed or cisplatin received the reduced dose for the remainder of the study. Patients who had two dose reductions and who experienced toxicity requiring a third dose reduction were discontinued from the study therapy. Cycle delays of up to 42 days were permitted for recovery from adverse events. Concomitant supportive therapies, such as granulocyte colony-stimulating factors or darbepoetin, were allowed.

**Data evaluation and analyses.** For efficacy, imaging using a contrast-enhanced CT scan or MRI scan was obtained at baseline, within 3 weeks before the start of treatment. Subsequently, the same imaging test was repeated every 6 weeks for response assessment. Response on imaging was determined by RECIST 1.0 criteria. For the first cycle, a complete blood count was done every week. Thereafter, treatment toxic effects including laboratory abnormalities were evaluated at each visit, using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The primary endpoint of the study was the ORR, defined as the proportion of patients showing complete response or partial response.

The study used Simon’s two-stage design to test the null hypothesis that the ORR was $\leq 30\%$ against the alternative hypothesis that it was at least 50% at the one-sided 0.05 significance level with a power of 0.80. During stage 1, 19 eligible patients would be accrued. If there were six or fewer patients who showed a response, the study would be stopped. Otherwise, the study would continue to the second stage of accrual, for a total of 39 evaluable patients. With a 10% dropout rate, 44 patients were enrolled to ensure 39 evaluable patients. Secondary end points included PFS, OS, and toxicity. All survival analyses were performed using the Kaplan–Meier method. Statistical analyses were performed using PASW statistics version 18 (IBM Co., Armonk, NY, USA).
21.4% of patients. Seven patients had a history of platinum-based adjuvant/neoadjuvant chemotherapy.

**Efficacy.** No patients experienced complete response, 27 patients (64.3%) experienced partial response, seven patients (16.7%) had stable disease, eight patients (19.0%) had progressive disease, and one patient (2.4%) had unknown response data due to clinical deterioration during cycle 1. The ORR was 64.3% (95% CI, 49.2%–77.0%), and the disease control rate (complete response + partial response + stable disease) was 81.0%. With a median follow-up duration of 14.3 months by the reverse Kaplan–Meier method (Schemper and Smith, 1996), the median PFS was 6.9 (95% CI, 6.2–7.6) months and the median OS was 14.4 (95% CI, 10.4–18.4) months (Figure 1).

**Treatment administration and toxicity.** The 42 enrolled patients received a total of 266 cycles of treatment. The median number of cycles administered was eight (range, 1–8). In our current study series, 3% of the cycles (8 of 266) had doses that were reduced: five because of nephrotoxicity and one each because of hepatotoxicity, hypersensitivity, or infection. In addition, 12.8% of cycles (35 of 266) were delayed, 33 because of hematologic toxicity. The mean dose intensities of pemetrexed and cisplatin were 94.9% (158.2 mg m$^2$ of 166.7 mg m$^2$) and 94.9% (22.1 mg m$^2$ of 23.3 mg m$^2$) of the planned weekly doses, respectively.

All treated patients were assessable for toxicity. Laboratory, including hematologic, and non-laboratory toxicities are summarized in Table 2. There were no deaths attributed to protocol treatment. Grade 3/4 neutropenia (28.6%) was the most common hematologic toxicity. Nonhematologic laboratory toxicities were uncommon. There were two instances of grade 3 hepatotoxicity and one instance of grade 3 nephrotoxicity. Grade 4 non-laboratory toxicity, a thromboembolic event, was observed in 1 of 42 patients. Grade 3 non-laboratory toxicity was reported in 7 of 42 patients including nausea, anorexia, fatigue, oedema, infection, and a thromboembolic event.

**DISCUSSION**

This current phase II trial demonstrated the ability of pemetrexed in combination with cisplatin to induce an ORR of 64.3% with a favourable toxicity profile in patients with advanced urothelial carcinoma.

---

**Table 1. Baseline characteristics (n = 42)**

| Characteristics          | n (%) |
|--------------------------|-------|
| Age                      |       |
| Median (range)            | 66.0 (42–78) |
| Gender                   |       |
| Female                   | 14 (33.3) |
| Male                     | 28 (66.7) |
| ECOG performance status  |       |
| 0                        | 3 (7.1) |
| 1                        | 39 (92.9) |
| Primary site             |       |
| Bladder                  | 23 (54.8) |
| Ureter                   | 11 (26.2) |
| Renal pelvis             | 8 (19.0) |
| Disease status           |       |
| Metastatic               | 18 (42.9) |
| Recurrent                | 24 (57.1) |
| Visceral metastasis      |       |
| Yes                      | 25 (59.5) |
| Metastatic sites         |       |
| Liver                    | 9 (21.4) |
| Lung                     | 20 (47.6) |
| Bone                     | 9 (21.4) |
| Bajorin risk group       |       |
| Intermediate             | 25 (59.5) |
| Low                      | 17 (40.5) |
| Prior therapy            |       |
| None                     | 35 (83.3) |
| Adjuvant/neoadjuvant     | 7 (16.7) |

Abbreviation: ECOG = Eastern Cooperative Oncology Group.

**Table 2. Adverse events (n = 42)**

| Toxicties               | All grade, n (%) | Grade 3, n (%) | Grade 4, n (%) |
|-------------------------|------------------|----------------|----------------|
| Laboratory              |                  |                |                |
| Neutropenia             | 26 (61.9)        | 10 (23.8)      | 2 (4.8)        |
| Anaemia                 | 23 (54.8)        | 2 (4.8)        | 0              |
| Thrombocytopenia        | 5 (11.9)         | 2 (4.8)        | 0              |
| AST/ALT elevation       | 4 (9.5)          | 2 (4.8)        | 0              |
| Creatinine elevation    | 6 (14.3)         | 1 (2.4)        | 0              |
| Non-laboratory          |                  |                |                |
| Nausea                  | 25 (59.5)        | 1 (2.4)        | 0              |
| Anorexia                | 24 (57.1)        | 1 (2.4)        | 0              |
| Constipation            | 12 (28.6)        | 0              | 0              |
| Mucositis               | 7 (16.7)         | 0              | 0              |
| Fatigue                 | 36 (85.7)        | 1 (2.4)        | 0              |
| Myalgia                 | 6 (14.3)         | 0              | 0              |
| Oedema                  | 7 (16.7)         | 1 (2.4)        | 0              |
| Infection               | 6 (14.3)         | 2 (4.8)        | 0              |
| Thromboembolic event    | 2 (4.8)          | 1 (2.4)        | 1 (2.4)        |

Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase.
Pemetrexed has undergone evaluation as a single agent in a phase II study for first-line and second-line treatment. In the first-line setting, 9 out of 28 evaluable patients achieved a partial response (32%, 95% CI, 16%–52%) with a disease control rate of 68%. The median response duration was 8.0 months and median overall survival was 9.4 months, which compare favourably with most single agents in this setting (Paz-Ares et al, 2006). In the second-line setting, the response rate was 28% and median overall survival was 9.6 months (Sweeney et al, 2006). The safety was promising after vitamin supplementation: grade 3–4 haematologic toxicities were reported in less than 9% of patients and severe non-haematologic toxicities developed in only one or two patients (Sweeney et al, 2006). However, another phase II trial in the second-line setting showed disparate results: the response rate was 8% failing to meet criteria for expanse after stage 1 and the febrile neutropenia developed in 15% of patients despite of vitamin supplementation (Galsky et al, 2007).

Pemetrexed in combination with gemcitabine was evaluated in phase II trials in advanced urothelial carcinoma. In European trial, gemcitabine 1250 mg m⁻² was administered on day 1 and day 8 of each 21-day cycle, and pemetrexed 500 mg m⁻² was given on day 8, 90 min after the gemcitabine administration (von der Maase et al, 2006). E4802 trial adopted the concept of sequence-dependent effect of pemetrexed, so on day 1, pemetrexed was administered first and followed 60 min later by gemcitabine 1000 mg m⁻², different from the European trial, on day 1 and day 8 (Dreicer et al, 2008). However, both combination regimens showed moderate antitumour activity; the response rates were 28% and 32%, respectively, with a median overall survival of 8 months and 13.4 months, respectively, while accompanied by significant haematologic toxicities (grade 3–4 neutropenia in 38% and 75%, respectively) and febrile neutropenia (17% and 11%, respectively) (von der Maase et al, 2006; Dreicer et al, 2008). This non-platinum combination has not been pursed since thereafter, so the role of pemetrexed, especially in chemotherapy-naive patients with urothelial carcinoma remains to be defined.

The combination of pemetrexed with cisplatin has already been evaluated in various types of malignancies. It demonstrated superior efficacy compared with cisplatin alone in malignant pleural mesothelioma (Vogelzang et al, 2003) and gemcitabine plus cisplatin combination in patients with nonsquamous non-small-cell lung cancer (Scagliotti et al, 2008). However, there was no published article on the efficacy and safety of pemetrexed combined with cisplatin in advanced urothelial carcinoma. Recently, results of phase I/II trials of biweekly pemetrexed (400 mg m⁻²) and cisplatin (50 mg m⁻²) were reported in an abstract; ORR was 39.5% (15/38, 95% CI, 24.0%–56.6%) and a median PFS was 6.7 months with a median OS of 10.5 months. Biweekly combination regimen also showed that favourable toxicities with the most frequent grade 3–4 toxicities were limited to neutropenia (13%) and anemia (5%) (Martin et al, 2013).

In the current study, the ORR of 64% and disease control rate of 81% is encouraging, particularly because patients with visceral metastasis comprised more than half of the patients enrolled. The median PFS was 6.9 months and the median OS was 14.4 months. Actually, the ORR, PFS, and OS in the current study overlaps a large number of other combination regimens reported in phase II and phase III trials (Vaughn et al, 1998; Dimopoulos et al, 1999; Bellmunt et al, 2000; von der Maase et al, 2000; Sternberg et al, 2001). Considering promising results of combination chemotherapy in phase II trials (Vaughn et al, 1998; Dimopoulos et al, 1999; Bellmunt et al, 2000), which failed to show superior outcome in phase III trials (Bamias et al, 2004; Dreicer et al, 2004; Bellmunt et al, 2012), caution should be taken when interpreting our phase II result and further comparative studies are needed in the future.

As expected, pemetrexed plus cisplatin combination chemotherapy was well tolerated in patients advanced urothelial carcinoma. The main toxicities of this regimen were haematologic, grade 3 or worse neutropenia in 29% of patients, but it did not lead to febrile neutropenia. Grade 3 or 4 non-haematologic toxicities were rare as these were observed in less than 5% of patients. The favourable toxicity observed in the current study is comparable with that observed in phase III study which compared pemetrexed plus cisplatin with gemcitabine plus cisplatin in non-small-cell lung cancer (Scagliotti et al, 2008). In that study, grade 3–4 neutropenia developed in 15%, anaemia in 6%, and thrombocytopenia in 4%, and febrile neutropenia occurred in only 1% in the pemetrexed plus cisplatin arm, which were significantly lower compared with gemcitabine plus cisplatin group. In our study, grade 3–4 neutropenia seems to be higher in frequency and it may be caused by the longer treatment duration, eight cycles rather than six cycles.

The excellent tolerability of this regimen allowed higher dose density of cisplatin (23.3 mg m⁻²/week) and more treatment cycles comparing with other cisplatin-based regimens (17.5 mg m⁻² per week and 4–6 cycles of methotrexate, vinblastine, Adriamycin, and cisplatin or gemcitabine/cisplatin) (von der Maase et al, 2000; Sternberg et al, 2006). Relatively higher dose density of cisplatin might contribute to better outcomes of the current regimen. Further studies to determine adequate dose intensity and treatment cycle numbers are needed in the future.

The convenience of the pemetrexed and cisplatin is of note. It does not require mid-cycle visit for chemotherapy and it requires less transfusion and supportive cares such as erythropoietin or granulocyte colony-stimulating factor than did patients on the gemcitabine plus cisplatin (Scagliotti et al, 2008). Although patients need vitamin B12 injection every 9 weeks and daily medication of folic acid, detailed patient education on the importance of vitamin supplementation and close monitoring could secure patient compliance. Furthermore, considering very favourable toxicity profile, this regimen might be served as a platform for additional combination of target agents in the future.

It would be of great importance to identify biomarkers for the prediction of the sensitivity of the tumour to pemetrexed. Among potential biomarkers, TS, a main target of pemetrexed, and folypolyglutamate synthetase, the enzyme responsible for activation of pemetrexed to its pharmacologically active form, have been shown to be promising predictors for various malignancies, especially in lung cancer and malignant mesothelioma (Takezawa et al, 2011; Christoph et al, 2012; Smit et al, 2012). Recently, a meta-analysis demonstrated that the response and clinical outcomes of patients with non-small-cell lung cancer treated by pemetrexed are better in those with a lower level of TS expression (Liu et al, 2013). Similarly, potential biomarkers should be evaluated in the future studies of pemetrexed in urothelial cancer to increase the success rate through enrichment and to individualize urothelial cancer treatment.

In conclusion, the combination of pemetrexed plus cisplatin combination given every 3 weeks is active and well tolerated in patients with advanced urothelial carcinoma in the first-line setting, and this regimen deserves further investigation.

ACKNOWLEDGEMENTS

We thank the patients and their families who took part in this study, the coordinators, and the investigators. We also thank Lilly Korea Co. for their kind donation of pemetrexed (Almita®) for this study. This study was supported in part by a grant (HI12C17880300, HI14C1931) from the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea.

Trials Registration: The trial was registered with the National Cancer Institute (www.clinicaltrials.gov identifier NCT01490437).
The authors have declared no conflict of interest.

**REFERENCES**

Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantzas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias A, Kosmidis P, Dimopoulos MA (2004) Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. *J Clin Oncol* 22(2): 220–228.

Bellmunt J, Guilem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Batiste-Alentorn E, Saenz A, Lopez-Brea M, Font A, Nogue M, Bastus R, Climent MA, de la Cruz J, Albanell J, Banus JM, Gallardo E, Diaz-Rubio E, Cortes-Funes H, Baselga J (2000) Phase II/II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. *J Clin Oncol* 18(18): 3247–3255.

Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, De Lena M, Lorusso V, Iacobellis U, Marzullo F, Maiello E, Cramarossa A, 2003 Review of a promising new agent-pemetrexed disodium. *Cancer* 97(58): 2056–2063.

Rossof AH, Talley RW, Stephens R, Thiggen T, Samson MK, Gropp J, Eyer HJ, Fisher R (1979) Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs. A Southwest Oncology Group Study. *Cancer Treat Rep* 63(9–10): 1557–1564.

Scagliotti GV, Pirkh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatemeier U, Digumarti R, Zukiun M, Lee JS, Mellemgaard A, Park K, Patil S, Rolki T, de Mani G, Gokel T, Simoni L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small-cell lung cancer. *J Clin Oncol* 26(21): 3543–3551.

Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. *Control Clin Trials* 17(4): 343–346.

Schultz RM, Patel VF, Worzalla J, Shih C (1999) Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. *Anticancer Res* 19(1A): 437–443.

Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM (1998) Multiple folate enzyme inhibition: mechanism of a novel pyrrolylpyrimidine-based antifolate LY231514 (MTA). *Adv Enzyme Regul* 38: 135–152.

Smit EF, Socinski MA, Mullaney BP, Myrard SP, Scagliotti GV, Lorigan P, Reck M, Ciuuleanu T, von Pawel J, Karaseva NA, Szczesna A, Ohanessian D, Powell E, Hozak RR, Hong S, Guba SC, Thatcher N (2012) Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Ann Oncol 23(7): 1723–1729.

Sterngberg CN, de Mulder P, Schornagel JH, Theodores S, Fossa SD, van Oosterom AT, Wijts JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C, Collette L, Group EG-UC (2006) Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. *Eur J Cancer* 42(1): 50–54.

Sterngberg CN, de Mulder PHM, Schornagel JH, Theodores C, Fossa SD, van Oosterom AT, Wijts F, Spina M, van Groeningen CJ, de Balincourt C, Collette L, Group EG-UC (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. *J Clin Oncol* 19(10): 2638–2646.

Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arming M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS (2006) Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. *J Clin Oncol* 24(21): 3451–3457.

Takayama K, Kamotani Y, Takahashi I, Kasa K, Tsukuba S, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K (2011) Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. *Br J Cancer* 104(10): 1594–1601.

Taylor EC, Kuhnert D, Shih C, Rinzell SM, Grindey GB, Barredo J, Janattapour M, Moran RG (1992) A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. *J Med Chem* 35(23): 4450–4454.

Vaughn DJ, Malkowicz SB, Zoltick B, Mick R, Ramchandani P, Holroyde C, Arvandinos G, Zervas A, Pantazopoulos D, Fountzilas G, Bamias A, Kyrkaikas Z, Anagnostopoulos A, Giannopoulos A, Kosmidis P (1999) Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. *Ann Oncol* 10(11): 1385–1388.

Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ, Eastern Cooperative Oncology Group (2003a) Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. *Cancer* 112(12): 2671–2675.

Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G (2004) Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. *Cancer* 100(8): 1639–1645.

Galsky MD, Mironov S, Iasonos A, Scottagerd J, Boyle MG, Bajorin DF (2007) Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. *Invest New Drugs* 25(3): 265–270.

Herr HW (1980) Cis-diaminedichloroplatinum II in the treatment of advanced bladder cancer. *J Urol* 123(6): 853–855.

Jenal A, Bray F, Center MM, Fleray J, Ward E, Forman D (2011) Global cancer statistics. CA *Cancer J Clin* 61(2): 69–90.

Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG (2013) Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. *Cancer Chemother Pharmacol* 72(5): 1125–1132.

Martin AL, Bellmunt J, maroto JP, Gallardo E, Brea ML, Perez-Gracia JL, Castellano DE, Valverde CM, Bezares S, Calvo E, Paz-Ares L (2013) Phase I/II study of biweekly pemetrexed plus cisplatin in patients with locally advanced, nonresectable or metastatic urothelial cancer: Safety and efficacy results from phase II. *J Clin Oncol* 31(suppl): abstr 4550.

Paz-Ares L, Bezares S, Tabernero JM, Castellanos D, Cortes-Funes H (2003a) Review of a promising new agent–pemetrexed disodium. *Cancer* 97(8 Suppl): 2056–2063.
von der Maase H, Lehmann J, Gravis G, Joensuu H, Geertsen PF, Gough J, Chen G, Kania M (2006) A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. *Ann Oncol* 17(10): 1533–1538.